The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Real-world outcomes of teclistamab treatment in R/R multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses a multi-center analysis of outcomes for patients with relapsed/refractory (R/R) multiple myeloma (MM) treated with the bispecific antibody teclistamab in real-world practice. Although a large proportion of the patients included in the analysis would not have been eligible for the MajesTEC-1 trial (NCT04557098), safety signals and response rates were comparable to those observed in the trial setting. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
